Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Efficacy and Safety of Rapamycin Therapy for Patients With Activated Phosphoinositide 3-Kinase δ Syndrome

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03383380
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:23.760158+00:00
Published At
2024-07-09T00:00:00+00:00
Record Updated At
2024-07-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Activated PI3K-delta Syndrome", "Immunodeficiency Primary"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-07-09"
protocolSection.identificationModule.nctId
"NCT03383380"
protocolSection.identificationModule.officialTitle
"Efficacy and Safety of Rapamycin Therapy for Patients With Activated Phosphoinositide 3-Kinase \u03b4 Syndrome"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Activated PI3K-delta Syndrome (protocolSection.conditionsModule.conditions)
  • Immunodeficiency Primary (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.